CTOs on the Move

Methapharm Inc

www.acic.com

 
Methapharm Inc is a Brantford, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.acic.com
  • 81 Sinclair Blvd
    Brantford, ON CAN N3S 7X6
  • Phone: 519.751.3602

Executives

Name Title Contact Details

Similar Companies

Unicep Packaging

Unicep Packaging is a Sandpoint, ID-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc., together with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., (collectively "Coeptis"), is a biopharmaceutical company developing innovative cell therapy platforms for cancer that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Coeptis` product portfolio and rights are highlighted by a universal, multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), and intellectual property and knowhow related to the GEAR™ cell therapy and companion diagnostic platforms, which Coeptis is developing with VyGen-Bio and leading medical researchers at the Karolinska Institutet. Coeptis` business model is designed around maximizing the value of its current product portfolio and rights through in-license agreements, out-license agreements and co-development relationships, as well as entering into strategic partnerships to expand its product rights and offerings, specifically those targeting cancer. The Company is headquartered in Wexford, PA.

harris pharmaceutical

harris pharmaceutical is a Fort Myers, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AccuMed

AccuMed Inc. is a Lawrence Township, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Argentis Pharmaceuticals

arGentis™ Pharmaceuticals, LLC is a private TN based pharmaceutical company with a mid-stage Orphan Drug treatment (ARG201) for late stage diffuse systemic scleroderma (dcSSc). The company is seeking capital or a partner to complete a Pivotal Clinical Trial which will enable obtaining marketing approval in the EU. The Company has a genotype marker (ROT1) that predicts patient response to treatment by oral tolerance for treatments like ARG201 for dcSSc. Furthermore, arGentis™ has a treatment for Rheumatoid arthritis (ARG301) that is in a Phase I Clinical Trial in the US.